While we have considerable data regarding the reproductive safety of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs), most studies have focused on the prevalence of major malformations in children with prenatal exposure to [...]
The first article on the list is one that relies on the Swedish medical registers to look neonatal outcomes in infants prenatally exposed to antidepressants. Â While the study does not generate new things to worry [...]
Multiple studies have demonstrated an increased risk of poor neonatal adaptation associated with exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants in late pregnancy. Â Results in the literature consistently indicate that about 25%-30% of infants [...]
Over the last few years, we have reported on several studies which have suggested an increased risk of certain types of cardiovascular malformations among children exposed to selective serotonin reuptake inhibitors (SSRIs) during pregnancy. The first reports [...]
Anxiety symptoms are relatively common during pregnancy but typically undiagnosed and undertreated. A recent study of 2793 women observed that 9.5% of women meet criteria for generalized anxiety disorder (GAD) at some point during their pregnancy. The highest rates of GAD were observed in the first trimester (7%). Only 2% of women met criteria for GAD in the second trimester, and 3% in the third trimester.
You can find a more recent post on this topic here: Venlafaxine and Duloxetine: Pooled Analysis Shows No Increase in Risk of Malformations We receive a fair number of questions on the use of duloxetine [...]
Click here to see an updated version of this post.
